Literature DB >> 22355516

Fatal course of foodborne botulism in an eight-month old infant.

Davide Lonati1, Carlo Alessandro Locatelli, Lucia Fenicia, Fabrizio Anniballi, Paolo Landri, Andrea Giampreti, Valeria Margherita Petrolini, Sarah Vecchio, Luigi Manzo.   

Abstract

An 8-month old girl, weighing 9 kg, was brought by her parents at 8.15 am to the Emergency Department (ED) for a progressive worsening of weakness and acute respiratory failure. On admission, the baby presented with poor oral intake, a weak cry and extremely weak muscular body control. Poor gag and suck, unreactive mydriasis, hypotonia, lethargy and absence of peristalsis were noted. Laboratory data showed severe respiratory acidosis. Chest X-ray, electroencephalography, encephalic CT scan and MRI were all normal, as were cerebrospinal fluid analysis and viral tests. Orotracheal intubation and continuous mechanical ventilation were applied. The patient received fluids, corticosteroids, aerosol therapy, large-spectrum antibiotics and enteral-nutrition. Further investigation revealed ingestion of an improperly prepared home-canned homogenized turkey meal. Type A botulinum neurotoxin was identified. Trivalent botulinum antitoxin, prostigmine and oral activated charcoal were administered. Generalized flaccid paralysis, areflexic bilateral mydriasis, gastric stasis and deep coma persisted for the duration of the hospital stay, and the patient died of severe respiratory failure and cardiac arrest 12 days after ED admission. Botulism poisoning should be suspected in any infant presenting with feeding difficulties, constipation, descendent paralysis or acute respiratory failure. Supportive treatment and antidotal therapy should be performed as soon as a clinical diagnosis is made. We describe a case of foodborne botulism in an 8-month old infant caused by ingestion of an improperly prepared home-canned homogenized turkey meal, representing the youngest fatal case reported in medical literature.

Entities:  

Keywords:  antidote; botulinum neurotoxins; infancy.; poisoning

Year:  2011        PMID: 22355516      PMCID: PMC3283199          DOI: 10.4081/pr.2011.e31

Source DB:  PubMed          Journal:  Pediatr Rep        ISSN: 2036-749X


Introduction

Botulism is a neuroparalytic disease caused by the blockade of neural transmission in the cholinergic synapses due to botulinum neurotoxins. These are mainly produced by the Clostridium botulinum or, rarely, by the neurotoxigenic Clostridium butyricum and Clostridium baratii. These neurotoxins can be distinguished in seven types (A–G). The human botulism is primarily related to types A, B, E and rarely to type F. All forms of botulism (foodborne, wound, infant botulism, adult intestinal toxemia, inhalational and iatrogenic botulism) are characterized by the same clinical syndrome, including an acute/subacute afebrile condition and symmetric descending flaccid paralysis.[1] Foodborne botulism is caused by ingestion of preformed toxin in food. The onset of clinical manifestations can be rapid and dramatic, differing from the infant form which usually develops less rapidly as the result of progressive intestinal colonization by neurotoxigenic clostridia and subsequent intraluminal production and absorption of toxin.[2] We describe here a case of foodborne botulism in an 8-month old infant caused by ingestion of an improperly prepared home-canned homogenized turkey meal, representing what is to our knowledge the youngest fatal case reported in medical literature.

Case Report

An 8-month old girl, weighing 9 kg, was brought by her parents at 8.15 am to the Emergency Department (ED) for a progressive worsening of weakness and dyspnea which had appeared two hours before. Medical history was negative for perinatal or delivery complications, and the baby was normal for development and growth; the mother had had no prenatal infections. Physical examination revealed a body temperature of 36.6°C, oxygen saturation of 86% on room air, blood pressure of 90/40 mmHg, pulse rate of 160 beats/min and respiratory rate of 44 breaths/min. The patient's general appearance was lethargic with pallor, poor oral intake, weak cry and weak muscular body control. Pulmonary clinical evaluation showed bronchostenosis, diffuse wheezing and murmur reduction at the right lower lung field. Laboratory analysis revealed white blood cell count of 15.9×109/L (27% neutrophils and 62% lymphocytes). Serum sodium level was 128 mEq/L, serum magnesium 1.7 mg/dL, blood glucose 178 mg/dL and lactate dehydrogenase 602 IU/L. All other parameters were in the normal range including hemoglobin (13.50 g/dL), hematocrit (40.7%), potassium (3.5 mEq/L), chloride (97 mEq/L) and calcium (9.9 mg/dL). Initial arterial blood gases on room air showed a pH value of 6.89, oxygen tension 36.4 mmHg, carbon dioxide tension 121 mmHg, bicarbonate 12.5 mmoL/L, lactate 2.2 mmoL/L and base excess of −9.4 mmoL/L with oxygen saturation of 48.4%. The patient was promptly intubated and treated with intravenous fluids (500 mL of 5% dextrose solution and 8 ml of 0.9% sodium chloride at a 30 ml/h infusion rate), hydrocortisone 80 mg intramuscularly, methylprednisolone 8 mg intravenously associated with adrenaline 0.5 mg, and beclometasone 0.8 mg by aerosol. Chest X-ray, EEG, cranial CT scan and MRI, as well as cerebrospinal analysis were all normal. Two hours after arrival in the ED the patient was transferred to the Paediatric Intensive Care Unit (PICU) of the nearest hospital where volume-cycled mechanical ventilation (FiO2 0.5, PaO2/FiO2 ratio 177.2) was started. At PICU admission, the infant was minimally responsive, with some visual response to pain, poor cough and minimal gag. Pulmonary clinical evaluation showed expiratory whistles and diffuse moist rales in both lungs; thick corpuscular secretions were aspirated through the oro-tracheal tube and collected for cultural assays. During the first six hours in PICU the clinical picture worsened to a lethargic and diffusely hypotonic child with unreactive mydriasis, poor gag and suck, and absence of peristalsis and tendon reflexes. Further investigation revealed that, the day before, the patient had ingested an improperly prepared home-canned homogenized turkey meal. Parents revealed that during the canning procedure, jars filled with turkey-meat had been boiled without a pressure cooker, stored at room temperature and not re-warmed before feeding. Foodborne botulism was suspected. Serum, food leftover samples (that appeared greenish and had a bad smell), rectal swabs and four unopened jars of food were immediately sent to the Italian National Reference Centre for Botulism at the National Institute of Health for laboratory analysis. Botulism poisoning was confirmed after ten hours. A mouse-bioassay testing of food leftovers was positive for type A toxin with 4000 Minimal Lethal Dose (MLD) per gram of food. C. botulinum type A was also detected by PCR assay and cultural method in both food leftovers and rectal swabs. On Day 2, electromyography showed low amplitude, short-duration, abundant motor-unit action potentials consistent with the described pattern of botulism poisoning.[3] During hospitalization, the patient received symptomatic treatment with fluids, enteral nutrition, methylprednisolone 10 mg bid, ranitidine 25 mg/day, 18% mannitol 10 ml/day, and large spectrum antibiotics (ceftazidime 250 mg bid for the first two days and subsequently ceftriaxone 700 mg/day). Fluconazole (400 mg/day) was started from Day 4, paracetamol (250 mg bid) from Day 5 and albumin (10 mL/day) from Day 6. Trivalent botulinum antitoxin was obtained from the Health Ministry stockpile and then administered intravenously (250 mL, 25 mL/h infusion rate) 10 h after laboratory confirmation of poisoning. Oral activated charcoal (5 g by nasogastric tube) and intravenous prostigmine (0.05 mg/kg bid) were also administered. Eight days after admission, an EEG revealed diffuse subcortical distress that worsened to a flat EEG during the following 24 h. Generalized flaccid paralysis, areflexic bilateral mydriasis, gastric stasis of 20–40 mL/die and deep coma with GCS 3 persisted for the duration of hospital stay, and the patient died from severe respiratory failure and cardiac arrest 12 days after ED admission.

Discussion

Botulism in infancy is rare. The ‘infant’ form is reported the most frequently under one year of age.[1,2,4] In one case of foodborne botulism described in the US, the patient (a six month-old infant) gradually recovered from a severe neuroparalytic picture after a 6-week period of intensive care.[5] Foodborne cases have also been reported in 1 to 2 year-old infants (2 fatal and 3 non-fatal cases) mostly due to ingestion of home-canned baby food.[5,6] In Italy, infant botulism has been the only form diagnosed in infants, with a total of 32 cases reported from 1984 to July 2011. Our case represents the first foodborne botulism involving an infant under the age of one year in Europe and the youngest fatal botulism case ever reported. The severe respiratory failure observed in this patient was consistent with ingestion of a large dose of type A toxin, the most potent type of botulinum neurotoxins.[7] Laboratory confirmation was made by the official mouse-bioassay (intraperitoneal injections of white mice unprotected and protected with polyvalent botulinum antitoxin) and real time PCR, a valuable technique recently introduced to detect pathogenic micro-organisms in food, environmental and clinical samples.[1,8] Based on the toxin level found in the food leftovers and the estimated consumption of about 50 g of contaminated food, the type A neurotoxin dose ingested by the patient was probably as high as 200,000 MLDs. The antidote used in this patient (250 mL Trivalent Equine Antitoxin, Behring) can induce passive immunization due to the neutralization of the circulating toxins. There are currently three different botulinum antitotoxin formulations available in Europe and the US (Table 1).[1,9,10,11] The Trivalent Equine Antitoxin is indicated for all forms of botulism. Notably, the recommended dose of the European antidote is approximately 50-fold higher compared to the US HBAT.
Table 1

Botulinum Antitoxin formulations available in Italy and in the US.

Botulinum AntitoxinFormulationAntitoxin typesConcentration per vial/ bottle (IU)Concentration per mL (IU)Dosage and route of administrationClinical indicationRef.
Trivalent equine antitoxin® (Behring)250 mL / bottleanti-A1875007502 bottles i.v.All botulism forms1
anti-B125000500
anti-E1250050
US HBAT investigational heptavalent equine antitoxin, (Cangene Corporation)20 mL / vialanti-A75003751 vial i.v.All botulism forms except infant botulism type A or B1, 9, 10
anti-B5500275
anti-C5000250
anti-D100050
anti-E8500425
anti-F5000250
anti-G100050
Botulism immune globulin intravenous (Human) (BIG-IV) (Baby BIG®) (Massachusetts public Health biologic Laboratories and cangene Corporation)Single-dose vial containing 100 mg±20 mg of lyophilized immunoglobulinanti-AAt least 152.0 mL/kgInfant botulism11
anti-BAt least 2.0(100 mg/kg) i.v.type A or B
In fact, the appropriate dosage for the antitoxin formulations currently used in botulism is still a subject of debate. In particular, for the European antidote, there is no information available in literature, nor any guidance from the manufacturer on the management of botulism in infancy. Recently, the US FDA has licensed an intravenous human-derived immune-globulin preparation (BabyBIG) for infant botulism (Table 1).[11] There is only one report describing the use of this product for treatment of foodborne disease in infancy.[5] Our patient received supportive therapy, gastrointestinal decontamination and antidotic treatment. Prostigmine was given to contrast the anticholinergic-induced ileus and facilitate removal of the contaminated food, spores and toxins from the gut.[1,12] Based on the estimated amount of the toxin ingested, the administered dose of the antitoxin was likely high enough to neutralize the circulating poison. Despite precise patient history, prompt laboratory investigation and treatment, clinical evolution was progressively rapid and fatal. Preventing food contamination remains the most relevant approach for botulism. People using home canning and food preservation processes should be educated about the correct time, pressure, and temperature required to destroy spores and botulinum toxins. Clinical manifestations of botulism in infancy may be difficult to recognize because of its insidious onset and the lack of a specific history.[13] The antidotic management of severe poisoning in infants has still not been clarified.
  12 in total

1.  Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-03-19       Impact factor: 17.586

Review 2.  Clinical spectrum of botulism.

Authors:  M Cherington
Journal:  Muscle Nerve       Date:  1998-06       Impact factor: 3.217

3.  Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1997-05-02

4.  Human botulism immune globulin for the treatment of infant botulism.

Authors:  Stephen S Arnon; Robert Schechter; Susan E Maslanka; Nicholas P Jewell; Charles L Hatheway
Journal:  N Engl J Med       Date:  2006-02-02       Impact factor: 91.245

Review 5.  Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities.

Authors:  Zygmunt F Dembek; Leonard A Smith; Janice M Rusnak
Journal:  Disaster Med Public Health Prep       Date:  2007-11       Impact factor: 1.385

6.  Denmark: botulism in an infant or infant botulism?

Authors:  A Paerregaard; O Angen; M Lisby; K Mølbak; M E Clausen; J J Christensen
Journal:  Euro Surveill       Date:  2008-12-18

Review 7.  Infant botulism.

Authors:  Lucia Fenicia; Fabrizio Anniballi
Journal:  Ann Ist Super Sanita       Date:  2009       Impact factor: 1.663

8.  Global occurrence of infant botulism, 1976-2006.

Authors:  Ruth Koepke; Jeremy Sobel; Stephen S Arnon
Journal:  Pediatrics       Date:  2008-07       Impact factor: 7.124

9.  Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975-1988.

Authors:  B A Woodruff; P M Griffin; L M McCroskey; J F Smart; R B Wainwright; R G Bryant; L C Hutwagner; C L Hatheway
Journal:  J Infect Dis       Date:  1992-12       Impact factor: 5.226

10.  [Sudden death of twins: botulism because of contamination by pap vegetables].

Authors:  D Fischer; A Freislederer; G Jorch
Journal:  Klin Padiatr       Date:  2004 Jan-Feb       Impact factor: 1.349

View more
  2 in total

1.  Treatment of foodborne botulism in current clinical toxicology.

Authors:  Afshin Mohammad Alizadeh; Nasim Zamani
Journal:  Pediatr Rep       Date:  2012-06-11

2.  Treatment of foodborne botulism in current clinical toxicology: authors' reply.

Authors:  Davide Lonati; Carlo Alessandro Locatelli; Lucia Fenicia; Fabrizio Anniballi; Paolo Landri; Andrea Giampreti; Valeria Margherita Petrolini; Sarah Vecchio; Luigi Manzo
Journal:  Pediatr Rep       Date:  2012-07-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.